CHARLOTTE, N.C., Feb. 07, 2017 -- Barings Global Short Duration High Yield Fund (the “Fund”) (NYSE:BGH) announced its monthly dividend for February 2017 of $0.1534 per share, payable on March 1, 2017. Based on the Fund’s January 31, 2016 share price of $20.05 per share, the distribution represents an annualized yield of 9.18% per share. Based on current projections through the payable date, the Fund expects that this distribution will be comprised of net investment income.
Additionally, the Fund announced estimated monthly distributions of $0.1534 per share for March 2017 and April 2017. The distribution schedule appears below:
| Month | Ex-Date | Record Date | Payable Date | Amount1 | |||||
| February | 02/15/2017 | 02/17/2017 | 03/01/2017 | $ | 0.1534 | ||||
| March | 03/21/2017 | 03/23/2017 | 04/03/2017 | $ | 0.1534 | ||||
| April | 04/18/2017 | 04/20/2017 | 05/01/2017 | $ | 0.1534 | ||||
The Fund seeks to pay a distribution at a rate that reflects net investment income actually earned. A portion of each distribution may be treated as paid from sources other than net investment income, including but not limited to short-term capital gain, long-term capital gain or return of capital. The final determination of the source and tax characteristics of these distributions will depend upon the Fund’s investment experience during its fiscal year and will be made after the Fund’s year end. The Fund will send to investors a Form 1099-DIV for the calendar year that will define how to report these distributions for federal income tax purposes.
The Fund is a non-diversified, closed-end management investment company that is managed by Barings LLC. The Fund invests primarily in short-duration, global high yield bonds with the objective of seeking as high a level of current income as Barings determines is consistent with capital preservation, with a secondary objective of capital appreciation. The Fund expects to maintain a weighted average portfolio duration, including the effects of leverage, of 3 years or less.
Cautionary Notice: Certain statements contained in this press release may be "forward looking" statements. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date in which they are made and which reflect management’s current estimates, projections, expectations or beliefs, and which are subject to risks and uncertainties that may cause actual results to differ materially. These statements are subject to change at any time based upon economic, market or other conditions and may not be relied upon as investment advice or an indication of the fund's trading intent. References to specific securities are not recommendations of such securities, and may not be representative of the fund's current or future investments. We undertake no obligation to publicly update forward looking statements, whether as a result of new information, future events, or otherwise.
Because the Fund is newly organized, its shares have a limited history of public trading. Investors should read the Fund’s prospectus and consider carefully the risks, investment objectives, charges and expenses associated with an investment in the Fund’s common shares. For a copy of the prospectus, please contact your securities representative.
About Barings
Barings is a $271 billion*global asset management firm dedicated to meeting the evolving investment and capital needs of our clients. We build lasting partnerships that leverage our distinctive expertise across traditional and alternative asset classes to deliver innovative solutions and exceptional service. A member of the MassMutual Financial Group, Barings maintains a strong global presence with over 600 investment professionals and offices in 17 countries. Learn more, at www.barings.com.
*As of December 31, 2016.
1 Amounts represent estimates for March and April.
17/104
Contact: Brian Whelan, Barings, (980) 417-7700, [email protected]


DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Italy Fines Apple €98.6 Million Over App Store Dominance
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 



